Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.
Int J Cardiol Heart Vasc
August 2021
Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich (LMU Munich), Munich, Germany.
Background: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk.
View Article and Find Full Text PDFMeta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y Inhibitor Thereafter.
J Atheroscler Thromb
July 2022
Klinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Aim: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is an ongoing debate and novel data has emerged. The aim of this meta-analysis was to assess outcomes of short vs. control DAPT duration.
View Article and Find Full Text PDFComparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture in Patients on Oral Anticoagulation - Post Hoc Analysis of the ISAR-CLOSURE Trial.
J Invasive Cardiol
September 2021
Klinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Muenchen, Lazarettstr. 36, 80363 Muenchen, Germany.
Article Synopsis
- The study aimed to compare vascular closure devices (VCDs) with manual compression (MC) for patients on chronic anticoagulation undergoing coronary angiography, focusing on access-site complications.
- Results showed that VCDs had similar rates of vascular complications compared to MC, but significantly lower rates of pseudoaneurysms and shorter time to hemostasis.
- The findings suggest that VCDs are a safe and effective alternative to MC in this patient population, improving outcomes related to healing time and complication rates.
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Eur Heart J Cardiovasc Pharmacother
September 2022
Population Health Research Institute, McMaster University, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada.
Aims: The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation.
Methods And Results: We searched MEDLINE, Embase, and CENTRAL from inception until September 2020. From 5446 citations, we selected randomized trials allocating patients with AF to antiplatelet therapy vs.
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.
EuroIntervention
October 2019
Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Aims: Clopidogrel is the P2Y12 inhibitor of choice in patients who undergo PCI and have an indication for oral anticoagulation (OAC). Prediction of the bleeding risk is of major interest in this population. The aim of this analysis was to investigate whether an enhanced platelet inhibition by clopidogrel measured by platelet function testing (PFT) with the Multiplate Analyzer is associated with an increased bleeding risk in patients on triple antithrombotic therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!